Arcus preps more phase 3 trials for TIGIT antibody, as Gilead opt-in beckonsArmed with a positive mid-stage trial readout in lung cancer, Arcus Biosciences will expand a phase 3 programme Share XArcus preps more phase 3 trials for TIGIT antibody, as Gilead opt-in beckonshttps://pharmaphorum.com/news/arcus-preps-more-phase-3-trials-for-tigit-antibody-as-gilead-opt-in-beckons/
GSK joins anti-TIGIT push with $625m upfront iTeos dealGlaxoSmithKline has staked a claim to the fast-moving category of cancer therapies targeting the TIGIT immune checkpoint, agreeing Share XGSK joins anti-TIGIT push with $625m upfront iTeos dealhttps://pharmaphorum.com/news/gsk-joins-ant-tigit-push-with-625m-upfront-iteos-deal/
BMS agrees deal worth up to $1.56bn for Agenus’ TIGIT cancer drugBristol-Myers Squibb has paid $200 million, and promised up to $1.36 billion in “biobucks” for exclusive rights to Share XBMS agrees deal worth up to $1.56bn for Agenus’ TIGIT cancer drughttps://pharmaphorum.com/news/bms-agrees-deal-worth-up-to-1-56bn-for-agenus-tigit-cancer-drug/
Roche nabs breakthrough tag for TIGIT cancer immunotherapyRoche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough Share XRoche nabs breakthrough tag for TIGIT cancer immunotherapyhttps://pharmaphorum.com/news/roche-nabs-breakthrough-tag-for-tigit-cancer-immunotherapy/
TIGIT Therapies Digital SummitHarnessing TIGIT Checkpoint Inhibitor Therapies Share XTIGIT Therapies Digital Summithttps://pharmaphorum.com/events/tigit-therapies-digital-summit/
